Plasma levels of prothrombin fragment F1+2, d-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients

Japanese Journal of Clinical Oncology

Volumn 38, Issue 1, 2008, Pages 2-7

  Kwon, Hyuk Chan ^a   Oh, Sung Yong ^a   Lee, Suee ^a   Kim, Sung Hyun ^a   Han, Jin Yeong ^a   Koh, Ri Young ^a   Kim, Min Chan ^a   Kim, Hyo Jin ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Coagulation test; Gastric cancer

Indexed keywords

D DIMER; FIBRINOGEN DEGRADATION PRODUCT; PROTHROMBIN; PROTHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PREDICTION; PREOPERATIVE EVALUATION; PROTHROMBIN TIME; RISK ASSESSMENT; STOMACH ADENOCARCINOMA; STOMACH CANCER; THROMBOCYTE COUNT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; PROTHROMBIN TIME; STOMACH NEOPLASMS;

EID: 39049140720     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym157     Document Type: Article

References (26)

1. Trousseau A. Clinique Medicale de L'Hotel Dieu de Paris. 2nd edn. Paris, Balliere 1865, 654-6.
2. Bick RL. Coagulation abnormalities in malignancy: A review. Semin Thromb Hemost 1992;18:353-72.
3. Luzzatto G, Schafer Al. The prethrombotic state in cancer. Semin Oncol 1990;17:147-59.
4. Editorial. Haemostatic abnormalities and malignant disease. Lancet 1986;8:303-4.
5. Hillen HF. Thrombosis in cancer patients. Ann Oncol 2000;11(S3): 273-6.
6. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA, et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993;54:793-806.
7. Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost 2003;29:291-300.
8. Gunji Y, Lewis J, Gorelik E. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. Blood Coagul. Fibrinolysis 1990;1:663-72.
9. Bruhn HD, Zurborn KH. Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. Blut 1983;46:85-8.
10. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 2004;30(1):5-20.
11. Di Micco P, Romano M, Niglio A, Nozzolillo P, Federico A, Petronella P, et al. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis 2001;33:546-50.
12. Rahr HB, Sorensen JV, Larsen JF, Jensen FS, Bredahl C. Markers of coagulation and fibrinolysis in portal blood from patients with and without gastric malignancy. Scand J Gastroenterol 1994;29(6):516-21.
13. Abbasciano V, Tassinari D, Sartori S, Trevisani L, Arcudi D, Bianchi MP, et al. Usefulness of coagulation markers in staging of gastric cancer. Cancer Detect Prev 1995;19(4):331-6.
14. Ikeda M Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9:287-91.
15. Lee JH, Ryu KW, Kim S, Bae JM. Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology 2004;51:1860-3.
16. Yamashita H, Kitayama J, Nagawa H. Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol 2005;35(10):595-600.
17. Yamashita H, Kitayama J, Kanno N, Yatomi Y, Nagawa H. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 2006;6:147.
18. Yamashita H, Kitayama J, Ishikawa M, Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 2007;95:324-31.
19. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002;88:745-9.
20. Frederick LG, David LP, Irvin DF, April GF, Charles MB, Daniel GH, et al. Stomach. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual, 6th edn. Philadelphia: Lippincott-Raven 2002;99-106.
21. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, et al. Plasma D-Dimer Levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000;18:600-8.
22. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001;17:667-73.
23. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997;52:563-5.
24. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 +2 fragment and thrombin-antithrombin complex. Blood 1982;59:1086-97.
25. Iversen LH, Okholm M, Thorlacius-Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease - a preliminary study. Thromb Haemost 1996;76:523-8.
26. Hanzal E, Tatra G. Prothrombin fragment F1+2 plasma concentrations in patients with gynecologic malignancies. Gynecol Oncol 1993;49:373-6.